MyelinWatch EL

INDEPENDENT RESEARCH MONITOR

Research on repairing myelin

Research specifically connected to remyelination or myelin repair, from laboratory work to studies in people.

A scan or laboratory change does not by itself prove that a person feels or functions better.

Newest research events first; the date MyelinWatch published each page is shown separately.

How the research sections relate

Emerging treatmentsTherapeutic developments for MS broadly — not only myelin repair.
Myelin repairResearch specifically aimed at remyelination or repairing myelin.
Studies & programmesThe combined catalogue containing both tracks; dual-track programmes appear once.

results

Research event/source date:
Myelin repairResults from peopleNo reported conclusion on effect

Published longitudinal imaging cohort study in people

MRI study follows a myelin-sensitive signal in MS lesions over about one year

Organisation: Second Hospital & Clinical Medical School, Lanzhou University · China

Researchers at the Second Hospital of Lanzhou University, China, used an MRI technique called APART-QSM, which separates a myelin-sensitive (diamagnetic) signal from an iron-sensitive one. At the first scan, white matter lesions had a lower myelin-sensitive signal than the corresponding normal-appearing white matter. In the 101 people with multiple sclerosis who had a second scan after a median of about one year, the myelin-sensitive signal in lesions increased. Larger increases were associated with female sex, ofatumumab treatment, relapsing-remitting MS and improvement in EDSS disability scores, and they were smaller with longer disease duration.

Published by MyelinWatch:

What this means for people with MS

The work tests whether this MRI method could track changes linked to remyelination. It does not show that myelin was restored, that ofatumumab repairs myelin, or that the signal explains changes in disability: this was an observational cohort with no randomised comparison of treatments, and about 30% of the people with MS had no follow-up scan. There is still no established approved treatment in clinical practice proven to reliably restore myelin in MS. It does not support a change to an individual treatment.

Read the update →Source: Journal of Magnetic Resonance Imaging (Wiley) — peer-reviewed primary article ↗
Research event/source date:
Myelin repairLaboratory or animal researchLess myelin damage and inflammation in mouse models; not clinical benefit

Mouse experiments; not tested in people

Mouse study links chronic demyelination to a dysfunctional microglial state

Organisation: Technical University of Munich and German Center for Neurodegenerative Diseases (DZNE) · Germany

Researchers at the Technical University of Munich and the German Center for Neurodegenerative Diseases (DZNE) compared mouse models of acute and chronic myelin loss. With chronic demyelination, microglia, the brain's immune cells, entered a distinct state with ongoing inflammation, fats trapped inside their lysosomes and fewer lipid droplets, together with higher cholesterol production and lower cholesterol export. A desmosterol-like compound (DMHCA) reversed this state, reduced inflammatory signalling and myelin damage, and improved movement in a mouse model of the inherited myelin disorder Pelizaeus–Merzbacher disease. In experimental autoimmune encephalomyelitis (EAE), a mouse model used to study MS, DMHCA lessened disease severity and reduced lesions. In post-mortem tissue from chronic active MS lesions of 3 people, about 75% of phagocytic immune cells (CD68+) carried a marker of this inflammatory state (CCL4), compared with about 13% in white matter from people without MS.

Published by MyelinWatch:

What this means for people with MS

The study points to a possible research target for chronic myelin damage, including in MS. The compound was given only to mice, EAE mice do not reproduce all features of MS, and the human finding is a small descriptive tissue observation, so the work cannot show that the compound would be safe or useful for people with multiple sclerosis. There is no established approved treatment in clinical practice proven to reliably restore myelin in MS. It does not support a change to an individual treatment.

Read the update →Source: Nature Neuroscience — peer-reviewed primary article ↗
Research event/source date:
Myelin repairLaboratory or animal researchMore maturing myelin-forming cells in aged rodents; not clinical benefit

Rat cell and mouse experiments; not tested in people

Rodent study: restoring BCL11A helped aged myelin precursor cells mature

Organisation: Altos Labs-Cambridge Institute of Science and University of Cambridge · United Kingdom

Researchers at Altos Labs-Cambridge Institute of Science and the University of Cambridge, UK, studied why oligodendrocyte progenitor cells, the precursor cells that can form new myelin, mature less well with age. Using a new computational method (gSWITCH) on gene-activity data from young and aged rats, they found several regulatory genes with lower activity in aged precursor cells and highlighted one, BCL11A. Blocking BCL11A reduced the maturation of these precursor cells into myelin-forming cells (oligodendrocytes). Adding BCL11A to precursor cells from aged rats in the lab increased the number of oligodendrocytes by about 54% without changing cell division. In 18-month-old mice, raising BCL11A in these cells with a viral gene vector before a chemically induced spinal cord lesion led to more maturing oligodendrocytes in the lesion 14 days later; the authors report no difference in lesion size.

Published by MyelinWatch:

What this means for people with MS

The study points to a gene that may help explain why myelin repair slows with age, a question relevant to MS. It did not test a treatment: BCL11A was raised by gene delivery in rodents, the lesion was chemically induced rather than an MS model, and the study counted maturing cells rather than measuring restored myelin or recovery of function. It cannot show that this approach would be safe or useful for people with multiple sclerosis. There is no established approved treatment in clinical practice proven to reliably restore myelin in MS. It does not support a change to an individual treatment.

Read the update →Source: eLife — peer-reviewed primary article ↗
Research event/source date:
Myelin repairResults from peopleNo reported conclusion on effect

Published matched observational biomarker study in people

Cholesterol and inflammation markers differ with severe progressive MS disability

Organisation: Annals of Clinical and Translational Neurology

Investigators compared blood lipids, apolipoproteins, nutritional and inflammatory markers in 53 people with severe progressive multiple sclerosis requiring skilled nursing and 53 matched community-dwelling people with progressive MS. The severe group had lower HDL cholesterol, ApoA-I, ApoA-II and albumin, and higher ApoB, ApoE and GlycA. Several lipid measurements were associated with disability scores. The analysis also found different networks of correlations among metabolic, inflammatory and neural-injury markers.

Published by MyelinWatch:

What this means for people with MS

The work may guide research into progressive-MS biology, including pathways relevant to repair. It cannot tell whether cholesterol changes cause disability, whether a cholesterol medicine would help, or whether myelin was restored. Disease severity, nutrition and other factors may influence the associations. It does not support a change to an individual treatment.

Read the update →Source: Annals of Clinical and Translational Neurology — peer-reviewed primary article ↗
Research event/source date:
Myelin repairLaboratory cells onlyNo reported conclusion on effect

Human-cell laboratory model, not a clinical study

Human spinal-cord organoids model oligodendrocyte states relevant to MS

Organisation: Stem Cell Reports

Researchers built human spinal-cord organoids and cortico-motor cell assemblies containing oligodendrocyte-lineage cells. Progenitor cells showed migration and neuronal inputs. After inflammatory-cytokine exposure, the cells developed gene-expression changes resembling some signatures found in MS tissue. This supplies a laboratory tool for studying cell states; the study did not administer a myelin-repair treatment to people.

Published by MyelinWatch:

What this means for people with MS

The model may help future mechanism studies, but resemblance to human MS tissue does not prove that myelin can be repaired in patients or that any medicine works. It offers no clinical access or treatment choice today. No approved treatment has been shown to reliably restore myelin in MS clinical practice.

Read the update →Source: Stem Cell Reports — PubMed indexed primary-article abstract ↗
Research event/source date:
Emerging treatments + myelin repairPlanned study in peopleStudy start-up agreement signed

Planned Phase 2 trial

Lucid-MS: study start-up agreement for a planned Phase 2 trial

Organisation: Quantum BioPharma / Lucid Psycheceuticals

Quantum BioPharma says it signed a Study Start-Up Agreement with Thermo Fisher Scientific's PPD clinical research business to prepare a planned Phase 2 trial of Lucid-21-302 (Lucid-MS) in people with progressive forms of multiple sclerosis (MS). The planned trial would compare Lucid-MS with placebo and assess efficacy, safety and tolerability.

Published by MyelinWatch:

What this means for people with MS

The agreement is an operational step toward a study. It does not establish that recruitment or dosing has begun, that Lucid-MS benefits people with MS, or that it repairs myelin. No approved treatment in clinical practice has been proven to reliably restore myelin in MS. No trial participation option in Greece was announced.

Read the update →Source: Quantum BioPharma — company announcement filed with the US Securities and Exchange Commission ↗
Research event/source date:
Myelin repairLaboratory cells onlyLaboratory model of myelin repair; no clinical outcome

Peer-reviewed laboratory model using human stem-cell-derived tissue; no patients treated

Human cell spheroids model myelin injury and repair in the laboratory

Organisation: Ramesan et al. research team

A Nature Neuroscience paper published on 1 October 2026 describes three-dimensional spheroids made from human induced pluripotent stem cells. They contain myelinating oligodendrocytes and responsive microglia. After experimentally induced myelin injury, researchers observed debris clearance, generation of new oligodendrocytes and new, thinner myelin sheaths around axons. Remyelination was observed in only about half of differentiations. Developmental maturity is another limitation: stem-cell-derived models may not fully reflect adult tissue. The model can help study repair mechanisms and screen candidate compounds, but a spheroid cannot reproduce all features of adult multiple sclerosis (MS).

Published by MyelinWatch:

What this means for people with MS

This is laboratory research, not a clinical trial or a treatment. No person with MS received an intervention in this study, and the paper does not demonstrate restored myelin or improved disability in patients. Any drug lead from this model would need separate testing.

Read the update →Source: Nature Neuroscience — Ramesan et al. — original peer-reviewed research article ↗Source: PubMed — Nature Neuroscience original article PMID 42823475 ↗
Research event/source date:
Emerging treatments + myelin repairRegistered study in peopleRecruitment update; no efficacy results posted

Registered early Phase 1/2a human study; estimated start remains October 2026

PRO-1562 study record now lists recruitment in Australia

ClinicalTrials.gov changed the overall status of NCT07826689 to Accepting participants and lists one site accepting participants in Adelaide, Australia. PRO-1562 is an experimental oral small molecule. The combined early study plans a Phase 1 safety part in healthy adults and a later Phase 2a part in people with relapsing MS and chronic optic neuropathy to test whether the drug may support myelin repair. Repair is a study objective, not a demonstrated effect. Its recorded start is still estimated for October 2026. The status change does not establish that anyone has enrolled or received PRO-1562, or that the MS part is open. No study results are posted.

Published by MyelinWatch:

What this means for people with MS

The registry now provides a recruitment lead in Australia, but it does not show a treatment benefit or availability in Greece. People interested in eligibility should use the current registry contacts; the planned MS cohort should not be assumed open from the overall status alone. There is no established approved treatment in clinical practice proven to reliably restore myelin in MS.

Read the update →Source: ClinicalTrials.gov — official clinical-trial registry ↗Source: Current NCT07826689 study record ↗
Research event/source date:
Myelin repairLaboratory or animal researchMouse/cell mechanism; no clinical result

Mouse and primary-cell research; unreviewed preprint

Virus-infected mice and myelin-making cells: an unreviewed Cx47 mechanism study

In a mouse coronavirus model and primary cell cultures, infection injured oligodendrocytes, the cells that make myelin, and reduced markers of mature, myelinating cells. This raises the possibility of impaired maturation or myelination. The preprint reports ERK2-driven phosphorylation, a chemical modification, at Ser372 on the Cx47 communication protein.

Published by MyelinWatch:

What this means for people with MS

This is a mechanistic finding, not a human MS study. It does not show that a virus causes MS, that myelin was repaired or that patients benefit. The preprint has not undergone peer review; this summary is based on its abstract. No established approved treatment in clinical practice has been proven to reliably restore myelin in MS.

Read the update →Source: bioRxiv — original preprint, not peer reviewed ↗
Research event/source date:
Myelin repairResults from peopleRegistry results; comparative effect not established

Small randomized feasibility study in people

Small exercise study posts results without establishing a comparative effect

Baseline median SSEP Z-scores were 3.83 for exercise and 2.87 for education, with 16 participants per group. Week-24 medians were 3.22 and 1.92, with 14 exercise and 15 education participants. No statistical comparison between the groups is posted.

Published by MyelinWatch:

What this means for people with MS

Somatosensory evoked potentials (SSEP) record the nervous system’s electrical response to sensory stimulation. These are separate medians, not individual changes or estimates of an exercise effect. They do not establish benefit to patients or remyelination. No established approved treatment in clinical practice has been proven to reliably restore myelin in MS.

Read the update →Source: ClinicalTrials.gov — Oregon Health and Science University — official ClinicalTrials.gov record ↗
Research event/source date:
Emerging treatments + myelin repairPeer-reviewed reviewReview of existing evidence

Peer-reviewed review

Stem-cell review separates immune treatment from experimental myelin repair

Autologous hematopoietic stem-cell transplantation (AHSCT) has the most mature clinical evidence for carefully selected highly active relapsing MS despite high-efficacy therapy, through immune reconstitution. Approaches using mesenchymal stromal cells (MSC) remain investigational, with inconsistent controlled-trial efficacy and safety concerns for intrathecal administration.

Published by MyelinWatch:

What this means for people with MS

These approaches are not interchangeable. Immune-treatment evidence does not establish direct myelin repair or a universal cure. No established approved treatment in clinical practice has been proven to reliably restore myelin in MS.

Read the update →Source: Medical Science Monitor — official research source ↗
Research event/source date:
Myelin repairLaboratory cells onlyLaboratory platform; no clinical efficacy evidence

Laboratory model with human-derived cells

A human-cell myelin model for studying treatment responses in the laboratory

Organisation: bioRxiv / Chunhui Tian and colleagues

Chunhui Tian and colleagues describe neural organoids on 3D-printed devices containing directional microfibres with oligodendrocyte progenitor cells, then add T cells and monocytes from people with MS. Laboratory responses distinguished responder and nonresponder profiles after exposure to prednisone, glatiramer acetate, interferon beta-1a or dimethyl fumarate.

Published by MyelinWatch:

What this means for people with MS

Human-derived cells are not a trial in patients. This model does not establish treatment efficacy, benefit to patients or remyelination in people. No approved treatment in clinical practice has been proven to reliably restore myelin in MS.

Read the update →Source: bioRxiv — original preprint, not peer reviewed ↗
Research event/source date:
Emerging treatments + myelin repairResults from peopleBiological signal in biomarkers, not proof of clinical benefit

Results from people

MSC-NP study finds CSF biomarker changes in two progressive MS cohorts

Organisation: Tisch Multiple Sclerosis Research Center of New York · United States

A published analysis examined cerebrospinal-fluid samples from two groups of people with secondary or primary progressive MS: 50 participants in a Phase 2 study and 43 in an expanded-access programme. After repeated intrathecal autologous MSC-NP treatment, CCL2, MMP9, SCF and CHIT1 changed in cerebrospinal fluid. NfL and GFAP did not show the same pattern of change.

Published by MyelinWatch:

What this means for people with MS

These findings may help measure biological response and guide future study design. They do not show remyelination, improvement in symptoms or disability, or an established benefit to patients.

Read the update →Source: Stem Cells Translational Medicine / Tisch Multiple Sclerosis Research Center of New York — peer-reviewed primary article ↗
Research event/source date:
Emerging treatments + myelin repairPlanned study in peopleA registry plan is not a study result

Planned Phase 1/2a study

PRO-1562 registry entry outlines a planned early study

The ClinicalTrials.gov record NCT07826689 describes a planned two-part study: single doses in healthy adults, followed by monthly doses in adults with relapsing MS and chronic optic neuropathy. The 17 September 2026 posting date and study details were available through a secondary mirror attributing them to ClinicalTrials.gov; they could not be independently checked against the primary record.

Published by MyelinWatch:

What this means for people with MS

This is a research plan, not a result. Current recruitment and whether the study has started remain unconfirmed.

Read the update →Source: ClinicalTrials.gov — official clinical-trial registry ↗Source: Veeva mirror reporting ClinicalTrials.gov data (secondary source) ↗
Research event/source date:
Myelin repairLaboratory or animal researchPositive laboratory or animal findings, not clinical benefit

Laboratory and animal research

Blocking fibronectin restored remyelination in experimental models

A PNAS study found that a protein called fibronectin can build up in areas where myelin has been lost. This may trap immature cells that could otherwise become myelin-making cells. Blocking fibronectin improved myelin repair and symptoms in two animal models.

Published by MyelinWatch:

What this means for people with MS

This points to an interesting new biological target, but the approach has not been tested in people and there is no approved medicine based on it.

Read the update →Source: PubMed / PNAS — peer-reviewed paper ↗
Research event/source date:
Myelin repairPeer-reviewed reviewReview of existing evidence

Peer-reviewed review

Review examines S1P modulators and myelin repair

Reviews cell, animal and human-marker studies of fingolimod, siponimod, ponesimod and ozanimod. Most repair evidence is laboratory-based; human imaging findings are indirect.

Published by MyelinWatch:

What this means for people with MS

Existing MS use of these medicines does not establish a remyelination indication. This is a review, not a new clinical trial. No established approved treatment in clinical practice has been proven to reliably restore myelin in MS.

Read the update →Source: Frontiers in Immunology — official research source ↗
Research event/source date:
Emerging treatments + myelin repairPreparing for a first study in peopleNo evidence of benefit in people yet

Preparing for human testing

Low-dose theophylline patch receives funding to prepare for its first study in people

Organisation: Johannes Gutenberg University Mainz · Germany

Claire Jacob's team at Johannes Gutenberg University Mainz announced €1.1 million to improve the skin patch, manufacture it to pharmaceutical standards and prepare a first safety study in healthy volunteers.

Published by MyelinWatch:

What this means for people with MS

The funding brings the patch closer to human testing, but the first study is not yet publicly registered and there is no evidence of benefit in people with MS.

Read the update →Source: Johannes Gutenberg University Mainz — official university research update ↗
Research event/source date:
Emerging treatments + myelin repairRegistered study in peopleNo reported conclusion on effect

Phase 3 study that can add or remove treatments

OCTOPUS: the first review of metformin and alpha-lipoic acid is planned for September 2026

Organisation: MRC Clinical Trials Unit at UCL · United Kingdom

The first OCTOPUS review in progressive MS will assess metformin and alpha-lipoic acid. It will look at brain shrinkage on MRI, disability, walking speed and hand function.

Published by MyelinWatch:

What this means for people with MS

This is one of the nearest important milestones in progressive MS. The review may decide which treatment groups continue, but it is not the final Phase 3 result.

Read the update →Source: OCTOPUS / MRC Clinical Trials Unit at UCL — official trial update ↗
Research event/source date:
Emerging treatments + myelin repairPlanned study in peopleFDA: hold lifted for planned Phase 2

Planned Phase 2 study

Lucid-MS: the FDA removed its temporary pause, allowing a planned Phase 2 study to move forward

Organisation: Quantum BioPharma / Lucid Psycheceuticals · Regulator: US Food and Drug Administration · United States

After an earlier temporary pause, the FDA allowed Lucid-MS to move forward. The company plans a Phase 2 study in progressive MS in which participants will be randomly assigned Lucid-21-302 or an inactive placebo, without knowing which one they receive.

Published by MyelinWatch:

What this means for people with MS

This is permission to begin testing, not evidence that the drug repairs myelin or improves people's health. As of 16 September 2026, no public study registration or participating centre had been found.

Read the update →Source: Quantum BioPharma — official company statement filed with the US SEC ↗
Research event/source date:
Emerging treatments + myelin repairLaboratory or animal researchPositive laboratory or animal findings, not clinical benefit

Laboratory and animal research

CN045 helped immature human cells mature and increased myelin repair in mice

Funder: US National Institutes of Health; National Multiple Sclerosis Society; Ohio Fast Forward

A paper in npj Drug Discovery described CN045, a molecule that can reach the brain and spinal cord. In the laboratory it helped immature human cells develop into cells that make myelin, and in mice it increased myelin repair.

Published by MyelinWatch:

What this means for people with MS

CN045 is an interesting possible drug, but it has not been tested in people. The molecule still needs improvement, safety checks and studies of how the body processes it.

Read the update →Source: npj Drug Discovery — peer-reviewed research article ↗
Research event/source date:
Emerging treatments + myelin repairResults from peopleLong-term safety observations; disability progressed

Retrospective follow-up of an open-label Phase 1 study

STEMS: long-term outcomes in 11 neural cell transplant recipients

Organisation: IRCCS San Raffaele Scientific Institute, Milan · Italy

A retrospective STEMS report published on 22 July 2026 follows 11 of the 12 original NCT03269071 recipients for a median 5.7 years after one injection of human fetal neural precursor cells into spinal fluid. Serious adverse events occurred but were judged unlikely related to the transplant. Median disability score EDSS rose from 7.25 before transplantation to 7.75 at two years and 8.5 at long-term follow-up. Median score on the cognition test SDMT was 38 at baseline, 49 at two years and 42 at long-term follow-up. Five of 11 had new or enlarged T2 MRI lesions without contrast enhancement.

Published by MyelinWatch:

What this means for people with MS

These are limited late-safety observations, not evidence that the intervention slowed disability or restored myelin. A lower gray-matter atrophy rate than in the first two years was an exploratory MRI observation. The small retrospective study had no concurrent randomized control, so it cannot show that the cells caused this difference or a benefit to patients. This remains an experimental intervention, not established treatment.

Read the update →Source: Stem Cell Research & Therapy / Springer Nature — peer-reviewed research article ↗Source: ClinicalTrials.gov — original STEMS Phase 1 ↗ Source: Nature Medicine — original STEMS report ↗
Research event/source date:
Myelin repairLaboratory or animal researchMixed findings

Mouse and brain-slice experiments before human testing

MMP-9 loss changed microglial responses but had little effect on remyelination in mice

Organisation: Acta Neuropathologica Communications

A study tested whether deleting matrix metalloprotease-9 (MMP-9) affects myelin injury and repair. In isolated brain slices, deficiency impaired repair through microglia/macrophage-related mechanisms. In the cuprizone mouse model, deficiency increased activated microglia/macrophages but had minimal impact on demyelination or remyelination. Proteomic and cell analyses pointed to altered inflammatory responses, not a demonstrated repair therapy.

Published by MyelinWatch:

What this means for people with MS

This helps map a complex repair-related pathway and cautions against assuming that suppressing MMP-9 will restore myelin. Mouse and slice findings cannot establish a treatment effect, safety, or benefit for people with MS. No approved clinical treatment has been shown to reliably restore myelin in MS.

Read the update →Source: Acta Neuropathologica Communications — peer-reviewed primary article ↗
Research event/source date:
Emerging treatments + myelin repairPlanned first study in peopleFDA: permission granted; first study not started

Planned Phase 1 study

PTD802: FDA permits a planned first study in people

Organisation: Pheno Therapeutics · Regulator: US Food and Drug Administration · United States

The FDA allowed a planned first study of PTD802 to proceed. The public listing reviewed here does not show that the study has started. PTD802 is an oral drug designed to help immature cells develop into cells that make myelin.

Published by MyelinWatch:

What this means for people with MS

Permission does not show that participants have received PTD802 or that it helps people with MS. This is not an available treatment.

Read the update →Source: Pheno Therapeutics — official company announcement ↗
Research event/source date:
Emerging treatments + myelin repairLaboratory or animal researchNo evidence of benefit in people yet

Laboratory and animal research

Rutgers advances new molecules that may help repair myelin

Organisation: Rutgers University · United States

Rutgers presented new small molecules that act on a receptor called mGluR5. They increased production of myelin proteins in human cells in the laboratory and showed activity in animal models.

Published by MyelinWatch:

What this means for people with MS

This is early research seeking a partner for further development, not a study in people. Researchers still need to select and improve the best candidate molecule.

Read the update →Source: Rutgers Innovation Ventures — university technology-transfer page ↗
Research event/source date:
Emerging treatments + myelin repairResults from peopleStudy stopped before a clear answer about whether it helps

Phase 3

RESTORE: the Phase 3 clemastine study stopped after an early review found it was unlikely to reach its goal

Study sponsor: Amsterdam UMC, location VUmc

RESTORE tested clemastine in people with MS and a disorder affecting eye movement. It was stopped after slow enrolment led to an early review, which found that the study was unlikely to reach its goal.

Published by MyelinWatch:

What this means for people with MS

This is an important negative development for this study. It should not be treated as a clear result about whether clemastine works, because the decision was made in a study that had serious difficulty finding participants.

Read the update →Source: ClinicalTrials.gov — official clinical-trial registry ↗
Research event/source date:
Emerging treatments + myelin repairRegistered study in peopleFirst patients enrolled and implanted; no results posted

Registered pilot study of a medical device in people; no results posted

SetPoint reports first patients enrolled and implanted in its MS pilot study

Organisation: SetPoint Medical

On 30 April 2026, SetPoint Medical announced that the first patients had enrolled and received implants in its pilot study for relapsing-remitting multiple sclerosis (MS). The device delivers electrical stimulation through an implant on the left vagus nerve, alongside continued standard disease-modifying treatment. The registry records the actual study start as 17 April 2026. In the registry update posted on 2 September 2026 and checked on 29 September, the study was accepting participants, with an estimated 60 participants and nine listed US sites. No results were posted. The April announcement is the event; the September dates refer to registry posting and verification.

Published by MyelinWatch:

What this means for people with MS

This milestone establishes that patients entered the study and received implants. It does not establish benefit to patients or myelin repair. Implantation involves surgery under anaesthesia. The device remains investigational and is not approved for MS; US approval for certain adults with rheumatoid arthritis is a different indication. The listed study sites are in the United States, with none listed in Greece at the registry check. Eligibility and site contact still determine participation. No established approved treatment in clinical practice has been proven to reliably restore myelin in MS.

Read the update →Source: SetPoint Medical — official company announcement ↗Source: ClinicalTrials.gov — NCT06796504; registry update posted 2 September 2026 ↗
Research event/source date:
Emerging treatments + myelin repairResults from peopleNo clear effect found

Phase 2

ReWRAP: Phase 2 found no statistically significant improvement in the study's measures of myelin repair

In ReWRAP, bazedoxifene was generally well tolerated. However, it did not show a clear improvement in either the main MRI measure of myelin or the study's other measures of whether the treatment worked.

Published by MyelinWatch:

What this means for people with MS

Another drug with strong results in laboratory and animal research did not show a clear sign of myelin repair in people in Phase 2.

Read the update →Source: ClinicalTrials.gov / ACTRIMS 2026 — official ClinicalTrials.gov record ↗
Research event/source date:
Emerging treatments + myelin repairLaboratory or animal researchPositive laboratory or animal findings, not clinical benefit

Laboratory and animal research

Bavisant / BRAVEinMS shows promising myelin repair and nerve protection in several experimental models

Organisation: Vita-Salute San Raffaele University and IRCCS San Raffaele Scientific Institute · Italy

After testing more than 1,500 existing compounds, researchers found that bavisant showed signs of myelin repair and nerve protection in several models. These included human cells in the laboratory and mice containing some human cells.

Published by MyelinWatch:

What this means for people with MS

This is one of the more promising new candidates among existing drugs, but it has not been tested in people with MS and no benefit to patients has been shown.

Read the update →Source: PubMed / Science Translational Medicine — peer-reviewed paper ↗
Research event/source date:
Emerging treatments + myelin repairLaboratory or animal researchPositive laboratory or animal findings, not clinical benefit

Laboratory and animal research

DITPA / Petratos: early results suggest nerve protection and myelin repair in mice

Organisation: Monash University · Australia

Steven Petratos's team reported that daily DITPA by mouth reduced neurological decline, helped myelin-making cells survive, reduced damage to myelin and nerve fibres, and improved related measurements in mice.

Published by MyelinWatch:

What this means for people with MS

This is an active and serious research programme, but there is no publicly registered study in people with MS. Results in mice are not evidence of benefit in people.

Read the update →Source: Research Square / Monash University — research preprint ↗
Research event/source date:
Emerging treatments + myelin repairResults from peopleDid not show the hoped-for effect

Phase 2

PIPE-307: the Phase 2 VISTA study did not show the hoped-for benefit

Organisation: Contineum Therapeutics · United States

In relapsing-remitting MS, PIPE-307 had acceptable safety and tolerability, but it did not reach the study's main or secondary measures of benefit.

Published by MyelinWatch:

What this means for people with MS

One of the most discussed drugs designed specifically to repair myelin did not show benefit in Phase 2. It is uncertain whether development for MS will continue.

Read the update →Source: Contineum Therapeutics — official company statement filed with the US SEC ↗
Research event/source date:
Emerging treatments + myelin repairResults from peoplePromising early finding

Phase 2a

CCMR Two: promising biological sign of myelin repair with metformin plus clemastine

Organisation: Cambridge Clinical MS Research Group · United Kingdom

After 24 weeks, metformin plus clemastine shortened the delay in the brain's electrical response to vision, a change consistent with myelin repair. Vision and disability did not improve during the study's short follow-up.

Published by MyelinWatch:

What this means for people with MS

This is one of the stronger early findings in people, but it does not yet show that the treatment improves symptoms or reverses disability.

Read the update →Source: Cambridge Clinical MS Research Group — official academic research-group update ↗

Studies & programmes →